See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $32.3B | 14.6x | -97.4x | |
| $22.9B | 5.3x | 19.2x | |
| $20.8B | 6.4x | 43.7x | |
| $14.0B | 14.4x | -65.9x | |
| $4.3B | 14.5x | 186.8x | |
| $3.8B | 8.8x | 94.0x | |
| $3.3B | 22.3x | -8.5x | |
| $3.1B | 6.1x | 23.8x | |
| $2.6B | 2.8x | 15.2x | |
| $2.4B | n/a | n/a | |
| $1.9B | 5.0x | -50.0x | |
| $1.9B | 3.0x | -36.0x | |
| $1.4B | 50.3x | -20.0x | |
| $1.4B | 2.3x | 19.0x | |
| $1.1B | 189.3x | -9.5x | |
| $1.0B | 6.4x | -7.1x | |
| $888M | 2.7x | 24.6x | |
| $852M | 2.3x | 22.7x | |
| $681M | 27.6x | -10.8x | |
| $639M | 0.8x | 20.6x | |
| $628M | 2.0x | 11.5x | |
| $603M | 8.6x | -7.6x | |
| $575M | n/a | -5.2x | |
| $549M | 96.4x | -2.8x | |
| $455M | 81.2x | n/a | |
| $420M | n/a | -3.3x | |
| $416M | 1.3x | -72.9x | |
| $363M | 4.8x | -7.9x | |
| $345M | n/a | n/a | |
| $309M | n/a | n/a | |
| $294M | 3.9x | -6.8x | |
| $272M | n/a | -31.9x | |
| $246M | 2.5x | n/a | |
| $241M | 66.3x | -4.4x | |
| $213M | 6.0x | -1.7x | |
| $201M | n/a | -1.1x | |
| $190M | 0.4x | -6.1x | |
| $145M | 2.2x | -3.3x | |
| $117M | 28.0x | -2.6x | |
| $115M | n/a | -1.3x | |
| $103M | 42.1x | -4.6x | |
| $99.9M | 17.3x | n/a | |
| $82.7M | 9.0x | -1.1x | |
| $48.3M | 2.0x | -0.3x | |
| $47.9M | 1.1x | n/a | |
| $29.2M | 3.1x | -0.2x | |
| $27.7M | 5.0x | n/a | |
| $22.6M | n/a | n/a | |
| $13.4M | n/a | n/a | |
| $13.2M | n/a | n/a | |
| $11.8M | 0.4x | n/a | |
| $8.2M | n/a | n/a | |
| $2.0M | n/a | n/a | |
| -$0.4M | -0.0x | n/a | |
| -$27.1M | -2.4x | n/a | |
| -$78.2M | -2.7x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine